Basics |
Sarepta Therapeutics, Inc.
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.
|
IPO Date: |
July 12, 2012 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$1.96B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$1.55 | 2.44%
|
Avg Daily Range (30 D): |
$0.66 | 3.84%
|
Avg Daily Range (90 D): |
$0.98 | 3.62%
|
Institutional Daily Volume |
Avg Daily Volume: |
1.75M |
Avg Daily Volume (30 D): |
13.26M |
Avg Daily Volume (90 D): |
9.32M |
Trade Size |
Avg Trade Size (Sh.): |
107 |
Avg Trade Size (Sh.) (30 D): |
135 |
Avg Trade Size (Sh.) (90 D): |
115 |
Institutional Trades |
Total Inst.Trades: |
13,445 |
Avg Inst. Trade: |
$4.06M |
Avg Inst. Trade (30 D): |
$3.45M |
Avg Inst. Trade (90 D): |
$3.25M |
Avg Inst. Trade Volume: |
.05M |
Avg Inst. Trades (Per Day): |
4 |
Market Closing Trades |
Avg Closing Trade: |
$8.79M |
Avg Closing Trade (30 D): |
$17.3M |
Avg Closing Trade (90 D): |
$14.85M |
Avg Closing Volume: |
112.25K |
|
|
Financials |
|
TTM |
Q2 2025 |
Q1 2025 |
Basic EPS
|
$-.57
|
$2.01
|
$-4.6
|
Diluted EPS
|
$-.81
|
$1.89
|
$-4.6
|
Revenue
|
$ 2.48B
|
$ 611.09M
|
$ 744.86M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -57.96M
|
$ 196.89M
|
$ -447.51M
|
Operating Income / Loss
|
$ -.93M
|
$ 115.58M
|
$ -300.39M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ 126.98M
|
$ 269.73M
|
$ -862.14M
|
PE Ratio
|
|
|
|
|
|
|